乙型肝炎病毒基因型对干扰素α2b应答的影响

Amplifing the HBVDNA of 1020 patients with chronic hepatitis B (CHB) under the HBV genotype-specific primers by polymerase chain reaction (PCR) , its amplified products was detected by Caliper-1000 microcurrent chip.Among them 136 patients were received interferon α2b for 6 months.All subjects were assessed for loss of HBeAg, presence of anti-HBe, suppression of HBVDNA, and normalization of serum alanine transaminase (ALT) .Among the 1020 patients.966 cases for HBV genotyping have been determined.At the end of treatment among 136 patients with CHB, the combined response (HBeAg loss, HBVDNA suppression and ALT normalization) to interferon α2b in the treatment of patients with HBV genotype B was superior in efficacy to patients with HBV genotype C and B/C (40.9% vs 25.8% and 16.7%;P>0.05) .The difference of HBV genotypes may have effect on response to interferon α2b in the treatment of CHB.